The hypothesis took hold in 2007, when a team from the University of Tartu in Estonia identified a set of
mutations in a large sample of Native American mitochondrial DNA.
Not exact matches
To identify the relevant
mutations the scientists analyzed the blood
samples of 1,858 men from three independent cohorts
in Europe and North America: the Swiss arm of the European Randomized Study for Prostate Cancer Screening, the
large American Screening trial, Prostate, Lung, Colorectal, and Ovarian (PLCO), Princess Margaret Cancer Centre (University Health Network) and Mount Sinai Hospital (Sinai Health System)
in Toronto.
Seven tumors, he says, is not a
large enough
sample to see the entire spectrum of
mutations in prostate cancer.
The authors conclude that «re-sequencing
in large samples of phenotypically extreme individuals, on the other hand, is much more likely to discover rare,
large - effect
mutations that are predicted... to be deleterious.»
The first manuscript entitled, Circulating Free Tumor - derived DNA (ctDNA) Determination of EGFR
Mutation Status in Real - World European and Japanese Patients with Advanced NSCLC: the ASSESS Study, used samples from the large ASSESS study to evaluate EGFR mutation status by analyzing ctDNA from blood
Mutation Status
in Real - World European and Japanese Patients with Advanced NSCLC: the ASSESS Study, used
samples from the
large ASSESS study to evaluate EGFR
mutation status by analyzing ctDNA from blood
mutation status by analyzing ctDNA from blood plasma.
So far this
mutation has been detected
in this breed only, with an estimated carrier frequency of 25 % based on a
large number of
samples collected form dogs originated from Finland, Sweden, United Kingdom and United States.